{"id":37095,"date":"2022-12-19T14:53:04","date_gmt":"2022-12-19T06:53:04","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=37095"},"modified":"2025-11-25T17:19:16","modified_gmt":"2025-11-25T09:19:16","slug":"vancomycin-hydrochloride-cas1404-93-9-apexbio-%e8%b2%a8%e8%99%9fb1223","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=37095","title":{"rendered":"Vancomycin hydrochloride | CAS#1404-93-9 APExBIO \u8ca8\u865fB1223"},"content":{"rendered":"

\u96f7\u5e15\u9ef4\u83cc\uff08Rapamycin\uff09<\/a>|\u00a0Romidepsin (FK228, depsipeptide)<\/a>\u00a0|\u00a0Daptomycin\u00a0<\/a>|\u00a0G-418 (80 S \u6838\u91a3\u9ad4\u5ef6\u4f38\u6291\u5236\u5291)<\/a><\/p>\n

Vancomycin hydrochloride is a hydrochloride of vancomycin that is a narrow-spectrum glycopeptide antibacterial agent.<\/p>\n

\"Vancomycin<\/p>\n

Vancomycin hydrochloride | CAS#1404-93-9 APExBIO\u00a0 \u8ca8\u865fB1223<\/a><\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Physical Appearance<\/td>\nA solid<\/td>\n<\/tr>\n
Storage<\/td>\nStore at -20\u00b0C<\/td>\n<\/tr>\n
M.Wt<\/td>\n1485.72<\/td>\n<\/tr>\n
Cas No.<\/td>\n1404-93-9<\/td>\n<\/tr>\n
Formula<\/td>\nC66<\/sub>H76<\/sub>Cl3<\/sub>N9<\/sub>O24<\/sub><\/td>\n<\/tr>\n
Solubility<\/td>\n\u226555.8 mg\/mL in DMSO with gentle warming; insoluble in EtOH; \u226522.15 mg\/mL in H2O<\/td>\n<\/tr>\n
SDF<\/td>\nDownload SDF<\/a><\/td>\n<\/tr>\n
Shipping Condition<\/td>\nShip with blue ice, or upon other requests.<\/td>\n<\/tr>\n
General tips<\/td>\nFor obtaining a higher solubility, please warm the tube at 37\u00b0C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n\n\n\n\n\n\n\n
Animal models<\/td>\nC57BL\/6 mice challenged with\u00a0Clostridium difficile (C. difficile)<\/em>\u00a0strain VPI 10463<\/td>\n<\/tr>\n
Dosage form<\/td>\n\n

20 mg\/kg<\/p>\n

Once daily by oral gavage for 5 days<\/td>\n<\/tr>\n

Applications<\/td>\nVancomycin treatment of infected mice was associated with improved clinical, diarrhea, and histopathology scores and survival during treatment. However, after discontinuation of the drug, clinical scores and histopathology were worse in treated mice than in untreated infected controls. Decreasing the duration of vancomycin treatment from 5 days to 1 day decreased recurrence and deaths in\u00a0C. difficile<\/em>\u00a0infection.<\/td>\n<\/tr>\n
Note<\/strong><\/td>\nThe technical data provided above is for reference only.<\/td>\n<\/tr>\n
<\/td>\n\n

References:<\/p>\n

1. Warren CA, van Opstal EJ, Riggins MS, et al. Vancomycin treatment’s association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrobial Agents and Chemotherapy, 2013, 57(2): 689-696.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/p>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

\"\"\u6297\u751f\u7d20\u985e\u5316\u5408\u7269<\/span><\/strong><\/span><\/p>\n